摘要
目的:观察二肽基肽酶Ⅳ抑制剂西格列汀治疗2型糖尿病非酒精性脂肪肝患者的临床疗效。方法:选取2016年4月-2017年10月在本院住院进行2型糖尿病非酒精性脂肪肝治疗的患者70例。按照随机数字表法将其分为试验组与对照组,每组各35例。对照组给予常规药物治疗,试验组在对照组基础上给予西格列汀片治疗,两组均治疗24周,比较两组治疗前后血糖(FBG、HbA1c、2 h PG)、血脂(TC、LDL-C、TG)、肝功能指标(AST、ALT、γ-GT)、胰岛素抵抗指数(HOMA-IR、HOMA-β)及脂肪肝的治疗效果。结果:治疗后,试验组FBG、HbA1c、2 h PG、TC、LDL-C、TG水平均低于对照组(P<0.05);治疗后,试验组HOMA-IR低于对照组,HOMA-β高于对照组,差异均有统计学意义(P<0.05);治疗后,试验组AST、ALT、γ-GT水平均低于对照组(P<0.05);治疗后,试验组有效率为74.29%,高于对照组的37.14%(P<0.05)。结论:在2型糖尿病非酒精性脂肪肝患者治疗的过程中,给予西格列汀治疗的方式能够有效提高脂肪肝的治疗效果,改善患者各项指标,降低血糖,改善胰岛素抵抗,效果显著,值得在临床应用推广。
Objective:To observe the clinical efficacy of dipeptidyl peptidaseⅣinhibitor Sigliptin in treatment of type 2 diabetes mellitus patients with non-alcoholic fatty liver.Method:A total of 70 patients with type 2 diabetes mellitus and non-alcoholic fatty liver treated in our hospital from April 2016 to October 2017 were selected.According to the random number table method,they were divided into experimental group and control group,35 cases in each group.The control group was given routine drug treatment,while experimental group was given Sigliptin tablets on the basis of control group,they were treated for 24 weeks.The blood sugar(FBG,HbA1 c,2 h PG),blood lipid(TC,LDL-C,TG),liver function index(AST,ALT,γ-GT),insulin resistance index(HOMA-IR,HOMA-β)before and after treatment,and the therapeutic effect of fatty liver between two groups were compared.Result:After treatment,the levels of FBG,HbA1 c,2 h PG,TC,LDL-C,TG in experimental group were lower than those of control group(P<0.05).After treatment,the HOMA-IR in experimental group was lower than that of control group,and HOMA-βwas higher than that of control group(P<0.05).After treatment,the levels of AST,ALT andγ-GT in experimental group were lower than those of control group(P<0.05).After treatment,the effective rate of experimental group was 74.29%higher than 37.14%of control group(P<0.05).Conclusion:Sigliptin in treatment of type 2 diabetes mellitus patients with non-alcoholic fatty liver disease,can effectively improve the therapeutic effect of fatty liver,improve the patient’s indicators,reduce blood sugar,improve insulin resistance,the effect is remarkable,and it is worth popularizing in clinical application.
作者
李祥兴
李冬玲
陈广建
刘洁
朱军军
尉秀清
LI Xiangxing;LI Dongling;CHEN Guangjian(Third Affiliated Hospital of Sun Yat-sen University Yuedong Hospital,Meizhou 514700,China)
出处
《中国医学创新》
CAS
2019年第19期14-18,共5页
Medical Innovation of China
基金
2017年梅州市科技计划项目(2017B130)
